Antiproliferative Effect of Vitamin D in Prostate Epithelial Cells
In the last decade, vitamin D and vitamin D analogs have emerged as potential chemotherapeutic agents for the treatment of a variety of cancers. The anticancer activity of vitamin D-based regimens is due, in large part, to inhibition of cell growth and promotion of cellular differentiation. Consistent with these cellular actions, compelling population-based and epidemiologic studies support the protective effects of vitamin D against prostate and certain other cancers. Cell cycle regulation is central to vitamin D’s antiproliferative effects. This chapter focuses primarily on the mechanisms of this cell cycle inhibition in prostate cancer cells and, for illustrative purposes, also highlights vitamin D effects on gene expression and cell cycle in cells derived from other solid tumors. Understanding the fundamental principles of vitamin D synthesis, metabolism and action has led to novel vitamin D-based therapeutic strategies, which are illustrated here. Finally, the possible molecular basis for resistance to vitamin D-mediated growth inhibition is considered.
KeywordsProstate Cancer Cell LNCaP Cell Anti Proliferative Effect Prostate Cancer Cell Line Human Prostate Cancer Cell
Unable to display preview. Download preview PDF.
- Berges RR, Vukanovic J, Epstein JI, CarMichel M, Cisek L, Johnson DE, Veltri RW, Walsh PC, Isaacs JT 1995 Implication of cell kinetic changes during the progression of human prostatic cancer. Clin Cancer Res 5:473–80Google Scholar
- Campbell MJ, Park S, Uskokovic MR, Dawson MI, Koeffler HP. 1998. Expression of retinoic acid receptor-beta sensitizes prostate cancer cells to growth inhibition mediated by combinations of retinoids and a 19-nor hexafluoride vitamin D3 analogy. Endocrinology 139:1972–1980.PubMedCrossRefGoogle Scholar
- Gross C, Skowronski RJ, Plymate SR, Rhim JS, Peehl DM, Feldman D. 1996. Simian virus 40-, but not human papillomavirus-, transformation of prostatic cells results in loss of growth-inhibition by 1,25-dihydroxyvitamin D3 Int J Oncology 8:41–47.Google Scholar
- Hedlund TE, Moffatt KA, Miller GJ, 1996a. Stable expression of the nuclear vitamin D receptor in the human prostatic carcinoma cell line JCA-1: evidence that the antiproliferative effects of 1 alpha, 25-dihydroxyvitamin D3 are mediated exclusively through the genomic signaling pathway. Endocrinology. 137:1554–1561.PubMedCrossRefGoogle Scholar
- Palmer HG, Gonzalez-Sancho JM, Espada J, Berciano MT, Puig I, Baulida J, Quintanilla M, Cano A, de Herreros AG, Lafarga M, Munoz A. 2001. Vitamin D(3) promotes the differentiation of colon carcinoma cells by the induction of E-cadherin and the inhibition of beta-catenin signaling. J Cell Biol. 154:369–387.PubMedCrossRefGoogle Scholar
- Rashid SF, Moore JS, Walker E, Driver PM, Engel J, Edwards CE, Brown G, Uskokovic MR, Campbell MJ. 2001. Synergistic growth inhibition of prostate cancer cells by 1 alpha,25 Dihydroxyvitamin D(3) and its 19-nor-hexafluoride analogs in combination with either sodium butyrate or trichostatin A. Oncogene. 20:1860–1872.PubMedCrossRefGoogle Scholar
- van den Bernd GJ, Pols HA, van Leeuwen JP. 2000. Anti-tumor effects of 1,25-dihydroxyvitamin D3 and vitamin D analogs. Curr Pharm Des. 2000 6:717–732.Google Scholar
- Yang ES, Maiorino CA, Roos BA, Knight SR, Burnstein, KL Vitamin D-mediated growth inhibition of an androgen-ablated LNCaP cell line model of human prostate cancer. Mol Cell Endocrinol (in press)Google Scholar